Insider Trading Alert - BKD, LLY And IMPV Traded By Insiders - TheStreet

Yesterday, Nov. 23, 2015, 96 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $660.00 to $25,301,360.70.

Highlighted Stocks Traded by Insiders:

Brookdale Senior Living (BKD) - FREE Research Report

Maul Glenn O., who is EVP & Chief People Officer at Brookdale Senior Living, sold 936 shares at $22.57 on Nov. 23, 2015. Following this transaction, the EVP & Chief People Officer owned 83,450 shares meaning that the stake was reduced by 1.11% with the 936-share transaction.

The shares most recently traded at $22.56, down $0.01, or 0.07% since the insider transaction. Historical insider transactions for Brookdale Senior Living go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 1,243
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 1,243
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 8,743

The average volume for Brookdale Senior Living has been 4.1 million shares per day over the past 30 days. Brookdale Senior Living has a market cap of $4.2 billion and is part of the health care sector and health services industry. Shares are down 38.18% year-to-date as of the close of trading on Monday.

Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates through five segments: Retirement Centers, Assisted Living, Continuing Care Retirement Communities (CCRCs)-Rental, Brookdale Ancillary Services, and Management Services. Currently, there are 3 analysts who rate Brookdale Senior Living a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BKD - FREE

TheStreet Quant Ratings

rates Brookdale Senior Living as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full

Brookdale Senior Living Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 205,000 shares at $84.54 on Nov. 23, 2015. Following this transaction, the 10% Owner owned 128.5 million shares meaning that the stake was reduced by 0.16% with the 205,000-share transaction.

The shares most recently traded at $83.23, down $1.31, or 1.58% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 200,000
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 925,000
  • 24-Week # shares bought: 17,157
  • 24-Week # shares sold: 1.2 million

The average volume for Eli Lilly and has been 5.6 million shares per day over the past 30 days. Eli Lilly and has a market cap of $93.6 billion and is part of the health care sector and drugs industry. Shares are up 22.83% year-to-date as of the close of trading on Monday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 2.37%. The company has a P/E ratio of 38.0. Currently, there are 7 analysts who rate Eli Lilly and a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings

rates Eli Lilly and as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Eli Lilly and Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Imperva (IMPV) - FREE Research Report

Shaya Yaniv, who is Senior VP, Engineering at Imperva, sold 10,313 shares at $74.16 on Nov. 23, 2015. Following this transaction, the Senior VP, Engineering owned 13,076 shares meaning that the stake was reduced by 44.09% with the 10,313-share transaction.

The shares most recently traded at $74.97, up $0.81, or 1.08% since the insider transaction. Historical insider transactions for Imperva go as follows:

  • 4-Week # shares sold: 2,030
  • 12-Week # shares sold: 2,030
  • 24-Week # shares sold: 2,688

The average volume for Imperva has been 574,500 shares per day over the past 30 days. Imperva has a market cap of $2.3 billion and is part of the technology sector and computer software & services industry. Shares are up 49.1% year-to-date as of the close of trading on Monday.

Imperva, Inc. develops, markets, sells, services, and supports cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. It operates in two segments, Imperva and Incapsula. Currently, there are 12 analysts who rate Imperva a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IMPV - FREE

TheStreet Quant Ratings

rates Imperva as a

sell

. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full

Imperva Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.